Posted by Michael Wonder on 03 Feb 2026
Acadia Pharmaceuticals provides update on regulatory submission for trofinetide for the treatment of Rett syndrome in the European Union
2 February 2026 - Acadia Pharmaceuticals today announced that the Company was informed by the CHMP of the EMA of a negative trend vote on its marketing authorisation application for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation.
Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion by the CHMP upon its formal adoption.
